- Home
- ANAB vs ZD Comparison
ANAB vs ZD Comparison
Compare ANAB & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | ZD |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ANAB | ZD |
|---|---|---|
| Price | $64.67 | $40.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $68.10 | $39.71 |
| AVG Volume (30 Days) | 442.0K | ★ 1.5M |
| Earning Date | 05-25-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ 1.15 |
| Revenue | $234,603,000.00 | ★ $1,364,028,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | $43.04 | $2.45 |
| P/E Ratio | ★ N/A | $34.53 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $15.32 | $22.45 |
| 52 Week High | $63.47 | $50.55 |
Technical Indicators
Market Signals| Indicator | ANAB | ZD |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 62.75 |
| Support Level | $43.67 | $34.96 |
| Resistance Level | N/A | $50.55 |
| Average True Range (ATR) | 3.61 | 2.58 |
| MACD | 0.67 | 1.34 |
| Stochastic Oscillator | 88.63 | 66.25 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ZD Ziff Davis Inc.
Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.